Celcuity’s (NASDAQ:CELC) lock-up period is set to expire on Monday, March 19th. Celcuity had issued 2,400,000 shares in its IPO on September 20th. The total size of the offering was $22,800,000 based on an initial share price of $9.50. After the expiration of Celcuity’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Celcuity (NASDAQ:CELC) opened at $16.14 on Monday. Celcuity has a 12-month low of $11.10 and a 12-month high of $22.73.
A number of institutional investors and hedge funds have recently made changes to their positions in CELC. Gagnon Securities LLC bought a new position in Celcuity in the 3rd quarter valued at $2,749,000. BlackRock Inc. bought a new position in Celcuity in the 4th quarter valued at $2,329,000. Royce & Associates LP bought a new position in Celcuity in the 3rd quarter valued at $1,371,000. Millennium Management LLC bought a new position in Celcuity in the 4th quarter valued at $231,000. Finally, Deutsche Bank AG bought a new position in Celcuity in the 4th quarter valued at $116,000. Hedge funds and other institutional investors own 13.79% of the company’s stock.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/03/12/celcuity-incs-celc-lock-up-period-set-to-end-on-march-19th.html.
Celcuity Company Profile
Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.